MRNA

Moderna, Inc.

Healthcare
45.64 -0.42 -0.91% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 18.11B
EV —
Shares Out 396.79M
Revenue (ttm) 2.23B
Net Income -3.19B
Beta —
P/E -5.64
Forward P/E —
EPS (ttm) $-8.14
P/S 8.10
P/B 2.43
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA -27.8%
ROE -38.01%
ROIC -40.09%
Gross Margin —
Oper. Margin -153.35%
Profit Margin -143.55%
Debt/Eq 0.17
LT Debt/Eq 7.38%
Quick Ratio —
Current Ratio 2.41
Book/sh 18.75
Cash/sh 4.83
Div Yield —
Div TTM —
Payout Ratio —
SMA20 -6.02%
SMA50 -8.59%
SMA200 21.16%
Volume 5,690,074
Avg Volume 8.36M
Rel Volume —
Perf Week -3.28%
Perf Month -2.29%
Perf Quarter -15.21%
Perf Half Y 64.77%
Perf YTD 54.76%
Perf Year 74.73%
Perf 3Y -64.59%
Perf 5Y -77.85%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, the company is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more. With a global team and unique culture, driven by company values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. The company currently has three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA (RSV vaccine). In 2025, Moderna achieved total revenue of $1.9 billion, largely from sales of its COVID vaccines. Beyond commercial products, Moderna continues to demonstrate the potential of its platform technology and is advancing a pipeline of development candidates across oncology, rare disease and infectious disease, including intismeran autogene in collaboration with Merck for melanoma and other tumor types, as well as candidates in seasonal flu, norovirus, propionic acidemia, and methylmalonic acidemia. Since 2022, the company has streamlined its production sites into a global manufacturing network to support new product launches and multi-year collaborations, including Moderna-built and managed facilities in the UK, Canada and Australia.

Name
Moderna, Inc.
Industry
Biotechnology
CEO
Stéphane Bancel · Chief Executive Officer
Employees
—
IPO Date
2021-02-22
Phone
(617) 714-6500
Address
325 Binney Street, Cambridge, MA 02142
Website
—

Key Executives

Name Title FY Pay
Elizabeth Nabel Director —
Abbas Hussain Director —
Sandra Horning Director —
Noubar Afeyan Chairman —
Stéphane Bancel Chief Executive Officer —

Latest News